IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Rebecca M. Henderson sold 4,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the completion of the sale, the director now directly owns 14,696 shares of the company’s stock, valued at approximately $3,985,114.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
IDXX stock opened at $279.88 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $176.11 and a twelve month high of $292.17. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 4.49. The company has a market capitalization of $24.28 billion, a P/E ratio of 65.70 and a beta of 0.84. The firm has a 50 day simple moving average of $279.53 and a 200-day simple moving average of $245.61.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.06. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The business had revenue of $620.10 million during the quarter, compared to the consensus estimate of $627.10 million. During the same quarter last year, the company earned $1.23 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, research analysts predict that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.
Several analysts have issued reports on the stock. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective for the company in a research report on Friday, May 3rd. Bank of America set a $300.00 price objective on shares of IDEXX Laboratories and gave the company a “buy” rating in a research report on Friday, June 21st. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $285.00 price objective on shares of IDEXX Laboratories in a research report on Friday, August 2nd. Finally, Guggenheim assumed coverage on shares of IDEXX Laboratories in a research report on Thursday, May 23rd. They issued a “buy” rating and a $276.00 price objective for the company. Seven analysts have rated the stock with a buy rating, IDEXX Laboratories has a consensus rating of “Buy” and an average price target of $286.67.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.